Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Cancer Research|November 17, 2007
Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesisNicholas T Woods, Hirohito Yamaguchi, Francis Y Lee, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Seminars in Hematology|May 16, 2002
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxideMichael E O'Dwyer, Paul La Rosée, Ramedivi Nimmanapalli, et al.
Statistical Methods in Medical Research|February 28, 2025
A new cure model accounting for longitudinal data and flexible patterns of hazard ratios over timeCan Xie, Xuelin Huang, Ruosha Li, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Haematologica|October 5, 2013
Advances in myelofibrosis: a clinical case approachJohn O Mascarenhas, Attilio Orazi, Kapil N Bhalla, et al.
Cancer Research|January 26, 2002
Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cellsHirohito Yamaguchi, Shanthi R Paranawithana, Michael W Lee, et al.
Blood Advances|August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phaseWarren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Pageof 13